Cat. No.: DAB-0012340
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat, Monkey, Bovine |
Applications | WB |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to a region surrounding Gly19 of human NME1/NDKA protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | NME1 |
UniProt No. | P15531 |
Gene ID | 4830 |
Gene Description | The NDK/NME/NM23 kinase family consists of at least eight distinct proteins that exhibit different cellular localization. Members of this group inhibit metastasis in a variety of tumor cell types. All NDK/NME/NM23 proteins possess nucleoside diphosphatase kinase activity and catalyze the phosphorylation of nucleoside diphosphate to the corresponding nucleoside triphosphate to regulate a diverse array of cellular events. At least four classes of NDK biochemical activities have been described, including protein-protein interactions, regulation of GTP-binding protein function, DNA-associated activities, and histidine-dependent protein phosphotransferase activity. NDK/NME proteins participate in the regulation of a broad spectrum of cellular responses, including development, differentiation, proliferation, endocytosis, and apoptosis. Because of its role in metastasis suppression and oncogenesis, NDKA has been widely studied. NDKA and NDKB are encoded by adjacent NME1 and NME2 genes and share 90% sequence identity. Two serine residues on NDKA/NM23-H1 can be phosphorylated by AMPKα1, but only phosphorylation at Ser122 determines whether NDKA channels ATP to AMPKα1. This regulates AMPKα1 activity towards ACC1, an important regulator of fatty acid metabolism. Mutation of NDKB/NM23-H2 at Ser122 in melanoma cells results in altered phosphoryl transfer activity. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.